An interventional study of Peer Intervention and Enhanced Usual Care in Opioid Use Disorder, Harm Reduction and Health Promotion, sponsored by University of Pennsylvania. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by University of Pennsylvania · Not applicable, Interventional, and Prevention
The purpose of the study is to develop an acceptable, feasible, and effective peer-led bundle of health resilience and promotion services to be delivered in the hospital setting, called the THRIVE intervention.
The main question it aims to answer is: Will participants receiving the THRIVE intervention have a reduced risk of self-reported non-fatal overdoses OR skin/soft tissue infections compared to participants receiving enhanced usual care?
Researchers will compare the THRIVE model to enhanced usual care to see if the THRIVE model helps participants reduce their number of self-reported non-fatal overdoses OR skin/soft tissue infections.
Intervention participants will:
Enhanced usual care participants will:
1,472 studies on the registry are indexed under Opioid-Related Disorders; 290 are open to participants now.
This study's planned enrollment of 262 is above the median of 63 across 1,166 interventional studies indexed under Opioid-Related Disorders.
Browse Opioid-Related Disorders studies →University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 235 are open to participants now.
Of its 158 completed or terminated interventional studies of FDA-regulated products, 109 (69%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: Peer Intervention
Other: Enhanced Usual Care
Participants will receive one peer-led, in-person session boosted by weekly text messages over a 12-week period.
Participants will receive a handout that includes health resilience education and resources in their local area as part of enhanced usual care.
Effectiveness of the THRIVE intervention compared to enhanced usual care (EUC) at lowering the incidence of non-fatal overdoses OR skin and soft tissue infections
Cumulative incidence of non-fatal overdose OR skin and soft tissue infection
Time frame: Baseline to 6 months
Effectiveness of the THRIVE intervention compared to EUC at lowering the incidence of non-fatal overdoses
Cumulative incidence of non-fatal overdose
Time frame: Baseline to 6 months
Effectiveness of the THRIVE intervention compared to EUC at lowering the incidence of skin and soft tissue infections
Cumulative incidence of skin and soft tissue infection
Time frame: Baseline to 6 months
Effectiveness of the THRIVE intervention on change in higher risk infection behaviors (characterized by BIRSI score) compared to EUC
Change in higher risk infection behaviors measured as the total score on the BIRSI
Time frame: Baseline to 6 months
Effectiveness of the THRIVE intervention on change in health resilience adoption compared to EUC (a)
(a) Change in the proportion of participants who self-report naloxone use in past 30 days to reverse another person's overdose
Time frame: Baseline to 6 months
Effectiveness of the THRIVE intervention on change in health resilience adoption compared to EUC (b)
(b) Change in the proportion of participants who self-report currently carrying naloxone
Time frame: Baseline to 6 months
Effectiveness of the THRIVE intervention on change in health resilience adoption compared to EUC (c)
(c) Change in the proportion of participants who self-report using at least one drug checking strategy in the past 30 days
Time frame: Baseline to 6 months
Effectiveness of the THRIVE intervention on health resilience access compared to EUC (a)
(a) Change in the proportion of participants who self-report having received at least one of: naloxone, syringes, or new or unused pipes in past 30 days
Time frame: Baseline to 6 months
Effectiveness of the THRIVE intervention on health resilience access compared to EUC (b)
(b) Change in the proportion of participants who self-report visiting a syringe services program in past 30 days
Time frame: Baseline to 6 months
Effectiveness of the THRIVE intervention on health resilience access compared to EUC (c)
(c) Change in the proportion of participants who self-report receiving any health resilience services from a needle exchange facility in past 30 days
Time frame: Baseline to 6 months
Heterogeneity of treatment effect by race (Black versus white) in the THRIVE intervention arm
Cumulative incidence of non-fatal overdose OR skin or soft tissue infection, by race (Black versus white)
Time frame: Baseline to 6 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.